Elgan Pharma Ltd.
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA (NCT05904626) | Elgan Pharma Ltd. | 2025-10-28 |
| Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants (NCT05670951) | Elgan Pharma Ltd. | 2025-02-27 |
Track Elgan Pharma Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.